Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE study (vol 26, pg 3523, 2008)

被引：1
|
作者：
Hochster
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 28期
关键词：
D O I：
10.1200/JCO.2008.19.8630
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4697 / 4697
页数：1
相关论文
共 50 条
  • [11] Bevacizumab in the first-line treatment of metastatic breast cancer (vol 6, pg 21, 2008)
    Cameron, David
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (15) : 2331 - 2331
  • [12] Efficacy and safety of bevacizumab in combination with irinotecan and capecitabine in first-line treatment of metastatic colorectal cancer
    Jungic, Sasa
    Tubic, Biljana
    Gajanin, Radoslav
    Gojkovic, Zdenka
    Rakita, Ivanka
    VOJNOSANITETSKI PREGLED, 2017, 74 (03) : 249 - 255
  • [13] The study of efficacy and safety of chemotherapy plus bevacizumab with oxaliplatin stop-and-go strategy in first-line treatment for metastatic colorectal cancer.
    Takano, Nao
    Nakayama, Goro
    Kodera, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [14] Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer
    Whyte, S.
    Pandor, A.
    Stevenson, M.
    Rees, A.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 47 - 53
  • [15] A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer
    R López
    M Salgado
    M Reboredo
    C Grande
    J C Méndez
    M Jorge
    C Romero
    G Quintero
    J de la Cámara
    S Candamio
    British Journal of Cancer, 2010, 103 : 1536 - 1541
  • [16] A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer
    Lopez, R.
    Salgado, M.
    Reboredo, M.
    Grande, C.
    Mendez, J. C.
    Jorge, M.
    Romero, C.
    Quintero, G.
    de la Camara, J.
    Candamio, S.
    BRITISH JOURNAL OF CANCER, 2010, 103 (10) : 1536 - 1541
  • [17] Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer
    Akun, E.
    Okutur, K.
    Seber, S.
    Korkmaz, T.
    Aydin, K.
    Bozkurt, M.
    Namal, E.
    Hasbal, B.
    Tecimer, C.
    Demir, G.
    JOURNAL OF BUON, 2012, 17 (04): : 669 - 676
  • [18] The efficacy and safety of XELOX plus bevacizumab with oxaliplatin stop-and-go strategy in first-line treatment for metastatic colorectal cancer: CCOG 0902 study
    Watanabe, Takuya
    Nakayama, Goro
    Ishigure, Kiyoshi
    Hayashi, Naomi
    Yaguchi, Toyohisa
    Kojima, Hiroshi
    Tsuboi, Kenji
    Ito, Akihiro
    Deguchi, Tomohiro
    Sekiya, Masanori
    Tanaka, Chie
    Ando, Yuichi
    Ohashi, Norifumi
    Kodera, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [19] Preliminary results of a randomized study of the safety and tolerability of three oxaliplatin-based regimens as first-line treatment for advanced colorectal cancer (CRC) ("Tree" study).
    Welles, L
    Hochster, H
    Ramanathan, R
    Wong, L
    Hart, L
    Shpilsky, A
    Jirau-Lucca, G
    Emanuel, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 254S - 254S
  • [20] RETROSPECTIVE STUDY TO EVALUATE EFFICACY AND SAFETY OF BEVACIZUMAB IN COMBINATION WITH BIWEEKLY XELIRI AS FIRST-LINE TREATMENT IN METASTATIC COLORECTAL CANCER
    Garcia Alfonso, P.
    Alvarez Suarez, S.
    Munoz Martin, A.
    Gonzalez del Val, R.
    Gutirrez Cabezon, L.
    Jerez Gilarranz, Y.
    Marquez-Rodas, I.
    Soria Lobelle, A.
    Riesco Martinez, M. C.
    Adeva Alfonso, J.
    ANNALS OF ONCOLOGY, 2010, 21 : I50 - I50
12345